company background image
MARKSANS logo

Marksans Pharma NSEI:MARKSANS 주식 보고서

최종 가격

₹162.75

시가총액

₹73.8b

7D

1.2%

1Y

75.4%

업데이트

22 Jun, 2024

데이터

회사 재무 +

Marksans Pharma Limited

NSEI:MARKSANS 주식 보고서

시가총액: ₹73.8b

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

MARKSANS 주식 개요

마크산스 제약은 자회사와 함께 전 세계에서 제네릭 의약품의 연구 개발, 제조, 마케팅 및 판매에 종사하고 있습니다.

회사 소개

MARKSANS 기본 분석
눈송이 점수
가치 평가3/6
미래 성장4/6
과거 실적3/6
재무 상태6/6
배당금3/6

보상

주가수익률( 22.8 x)이 Indian 시장( 32.3 x)보다 낮습니다.
수익은 매년 21.63% 증가할 것으로 예상됩니다.
지난 1년간 수익이 18.2% 증가했습니다.
동종업계 및 업계 대비 좋은 가치로 거래

위험 분석

높은 수준의 비현금 수입
0.38% 의 배당금은 현금 흐름으로 잘 감당되지 않습니다.

Marksans Pharma Limited 경쟁사

FDC

BSE:531599

₹74.9b

Neuland Laboratories

BSE:524558

₹84.2b

Blue Jet Healthcare

NSEI:BLUEJET

₹73.6b

Procter & Gamble Health

BSE:500126

₹84.0b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Marksans Pharma
과거 주가
현재 주가₹162.75
52주 최고치₹185.50
52주 최저치₹90.15
베타1.62
11개월 변경-3.73%
3개월 변경 사항11.89%
1년 변경 사항75.38%
33년 변화86.75%
5년 변화691.97%
IPO 이후 변화-40.15%

최근 뉴스 및 업데이트

Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Jun 07
Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?

May 31
Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?

Recent updates

Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Jun 07
Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?

May 31
Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?

Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)

Feb 16
Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)

Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors

Jan 26
Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors

We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease

Dec 02
We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease

Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly

Jun 21
Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly

Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Nov 17
Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation

Sep 16
This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation

Marksans Pharma (NSE:MARKSANS) Is Increasing Its Dividend To ₹0.25

Sep 01
Marksans Pharma (NSE:MARKSANS) Is Increasing Its Dividend To ₹0.25

Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt

Jun 14
Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt

Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

May 27
Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

Is Marksans Pharma (NSE:MARKSANS) A Risky Investment?

Feb 19
Is Marksans Pharma (NSE:MARKSANS) A Risky Investment?

Marksans Pharma Limited's (NSE:MARKSANS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Feb 04
Marksans Pharma Limited's (NSE:MARKSANS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Here's Why We Think Marksans Pharma (NSE:MARKSANS) Is Well Worth Watching

Jan 20
Here's Why We Think Marksans Pharma (NSE:MARKSANS) Is Well Worth Watching

Do Institutions Own Marksans Pharma Limited (NSE:MARKSANS) Shares?

Jan 05
Do Institutions Own Marksans Pharma Limited (NSE:MARKSANS) Shares?

Shareholders Are Thrilled That The Marksans Pharma (NSE:MARKSANS) Share Price Increased 250%

Dec 21
Shareholders Are Thrilled That The Marksans Pharma (NSE:MARKSANS) Share Price Increased 250%

What Can We Conclude About Marksans Pharma's (NSE:MARKSANS) CEO Pay?

Dec 06
What Can We Conclude About Marksans Pharma's (NSE:MARKSANS) CEO Pay?

These 4 Measures Indicate That Marksans Pharma (NSE:MARKSANS) Is Using Debt Safely

Nov 19
These 4 Measures Indicate That Marksans Pharma (NSE:MARKSANS) Is Using Debt Safely

Marksans Pharma Limited's (NSE:MARKSANS) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?

Nov 04
Marksans Pharma Limited's (NSE:MARKSANS) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?

If You Like EPS Growth Then Check Out Marksans Pharma (NSE:MARKSANS) Before It's Too Late

Oct 20
If You Like EPS Growth Then Check Out Marksans Pharma (NSE:MARKSANS) Before It's Too Late

Is Marksans Pharma Limited's (NSE:MARKSANS) Shareholder Ownership Skewed Towards Insiders?

Oct 05
Is Marksans Pharma Limited's (NSE:MARKSANS) Shareholder Ownership Skewed Towards Insiders?

If You Had Bought Marksans Pharma (NSE:MARKSANS) Shares A Year Ago You'd Have Earned273% Returns

Sep 20
If You Had Bought Marksans Pharma (NSE:MARKSANS) Shares A Year Ago You'd Have Earned273% Returns

A Look At The Fair Value Of Marksans Pharma Limited (NSE:MARKSANS)

Aug 20
A Look At The Fair Value Of Marksans Pharma Limited (NSE:MARKSANS)

Many Still Looking Away From Marksans Pharma Limited (NSE:MARKSANS)

Aug 05
Many Still Looking Away From Marksans Pharma Limited (NSE:MARKSANS)

If You Like EPS Growth Then Check Out Marksans Pharma (NSE:MARKSANS) Before It's Too Late

Jul 08
If You Like EPS Growth Then Check Out Marksans Pharma (NSE:MARKSANS) Before It's Too Late

주주 수익률

MARKSANSIN PharmaceuticalsIN 마켓
7D1.2%-1.7%-0.1%
1Y75.4%50.6%46.3%

수익률 대 산업: MARKSANS 지난 1년 동안 51.1 %를 반환한 Indian Pharmaceuticals 산업을 초과했습니다.

수익률 대 시장: MARKSANS 지난 1년 동안 43.7 %를 반환한 Indian 시장을 초과했습니다.

가격 변동성

Is MARKSANS's price volatile compared to industry and market?
MARKSANS volatility
MARKSANS Average Weekly Movement7.2%
Pharmaceuticals Industry Average Movement5.9%
Market Average Movement6.5%
10% most volatile stocks in IN Market9.5%
10% least volatile stocks in IN Market4.3%

안정적인 주가: MARKSANS 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.

시간에 따른 변동성: MARKSANS 의 주간 변동성( 7% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립직원CEO웹사이트
1992852Mark Saldanhamarksanspharma.com

마크산스 파마는 자회사와 함께 전 세계에서 제네릭 의약품의 연구 개발, 제조, 마케팅, 판매에 종사하고 있습니다. 이 회사는 진통제, 양성 전립선 비대증, 항당뇨, 간질, 항염증, 부갑상선 기능 항진증, 당뇨병, 제산제, 신경학, 심혈관, 호르몬, 종양학, 위장병학, 항당뇨, 통증 관리, 부인과, 항진균, 항궤양제, 비타민, 피부과, 세팔로스포린, 주사제, 항 알레르기, 항균 및 고혈압 치료 분야의 제품을 공급합니다. 마크산스 제약은 1992년에 설립되었으며 인도 뭄바이에 본사를 두고 있습니다.

Marksans Pharma Limited 기본 사항 요약

Marksans Pharma 의 수익과 매출은 시가총액과 어떻게 비교하나요?
MARKSANS 기본 통계
시가총액₹73.75b
수익(TTM)₹3.14b
수익(TTM)₹21.77b

23.5x

P/E 비율

3.4x

P/S 비율

MARKSANS 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
MARKSANS 손익 계산서(TTM)
수익₹21.77b
수익 비용₹10.38b
총 이익₹11.39b
기타 비용₹8.26b
수익₹3.14b

최근 보고된 수익

Mar 31, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)6.92
총 마진52.32%
순이익 마진14.41%
부채/자본 비율1.4%

MARKSANS 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

배당금

0.4%

현재 배당 수익률

9%

지급 비율